RZLT News and Press, Rezolute Inc. From 05/30/24

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, tod...

2024-05-22 10:00:31 ET More on etc. Replimune: Continuing To Justify The Bear Thesis (For Now) Gold At $3,000 Is The Wrong Way To Think About The Precious Metal Best Buy: Poised For Growth Amid E-Commerce Threat Nvidia’s upcoming earnings has investors...

2024-05-21 17:07:24 ET More on Rezolute Seeking Alpha’s Quant Rating on Rezolute Historical earnings data for Rezolute Financial information for Rezolute Read the full article on Seeking Alpha For further details see: Rezolute stock rockets...

Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease intervention Virtual investor event to be held today at 5:30pm ET REDWOOD C...

2024-05-16 10:59:17 ET More on Rezolute Seeking Alpha’s Quant Rating on Rezolute Historical earnings data for Rezolute Financial information for Rezolute Read the full article on Seeking Alpha For further details see: Rezolute reports Q3 re...

Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Completed in-vivo toxicology study in brown Norway rats; early results show no abnormalities at highest tested dose of RZ...

REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, t...

Shares of Rezolute, Inc. (NASDAQ: RZLT) traded at a new 52-week high today and are currently trading at $2.99. So far today, approximately 207.71k shares have been exchanged, as compared to an average 30-day volume of 238.24k shares. Rezolute, Inc., a clinical stage biopharmaceutical company,...

REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, t...

Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FD...